natgillin/translations-raw huggingface dataset:
The 6-mecaptopurine oral suspension and tablet are not bioequivalent with respect to peak plasma concentration, and therefore intensified haematological monitoring of the patient is advised on switching formulations (see section 5.2).
Oralna suspenzija 6-merkaptopurina i tablete nisu bioekvivalentne s obzirom na vršne koncentracije u plazmi te se stoga savjetuje intenzivno praćenje hematoloških parametara u bolesnika pri zamjeni farmaceutskih oblika lijeka (vidjeti dio 5.2).
6-mercaptopurine causes embryolethality and severe teratogenic effects in the mouse, rat, hamster and rabbit at doses that are non-toxic to the mother.
6-merkaptopurin uzrokuje smrt embrija i teške teratogene učinke na mišu, štakoru, hrčku i kuniću u dozama koje nisu toksične za majku.
Transient profound oligospermia has been reported following exposure to 6-mercaptopurine in combination with corticosteroids.
Prolazna izrazita oligospermija zabilježena je nakon izloženosti 6-merkaptopurinu u kombinaciji s kortikosteroidima.
Substantial dose reductions are generally required for homozygous-TPMT deficiency patients to avoid the development of life threatening bone marrow suppression.
Znatne redukcije doze općenito su nužne u bolesnika koji su homozigoti za deficit TPMT-a kako bi se izbjegla životno ugrožavajuća supresije koštane srži.
*inflammatory bowel disease (IBD) is an unlicensed indication
*upalna bolest crijeva (UBC) nije odobrena indikacija
Xanthine oxidase is the main catabolic enzyme and it converts the 6-mercaptopurine into the inactive metabolite, 6-thiouric acid.
Ksantin oksidaza je glavni katabolički enzim koji pretvara 6-merkaptopurin u inaktivni metabolit, 6-tiouričnu kiselinu.
Your can take your medicine with food or on an empty stomach but the choice of method should be consistent from day to day.
Možete uzeti svoj lijek s hranom ili natašte, ali na isti način svaki dan.
It is recommended that the healthcare professional advises the patient or carer which syringe to use to ensure that the correct volume is administered.
Zdravstvenom djelatniku se preporučuje da savjetuje bolesniku ili njegovom njegovatelju koje štrcaljke koristiti kako bi osigurao primjenu točnog volumena.
Since there is a potential for reduced elimination of mercaptopurine, consideration should be given to reduced starting doses in patients with impaired hepatic function.
S obzirom na mogućnost smanjene eliminacije merkaptopurina, dolazi u obzir smanjenje početne doze u bolesnika s oštećenom funkcijom jetre.
Very common (affects more than 1 in 10 people) - a drop in the number of white blood cells and platelets (may show up in blood tests)
Vrlo često (javljaju se više od 1 na 10 osoba) - pad broja bijelih krvnih stanica (leukocita) i trombocita (može se pokazati u krvnim testovima)
The larger 5 ml syringe (white), marked 1 ml to 5 ml, is for measuring doses of more than 1 ml.
Veća štrcaljka od 5 ml (bijela), označena s 1 ml do 5 ml, služi za mjerenje doza većih od 1 ml.
Hepatosplenic T-cell lymphoma has been reported in patients with inflammatory bowel disease* treated with azathioprine (the prodrug to 6-mercaptopurine) or 6-mercaptopurine, either with or without concomitant treatment with anti-TNF alpha antibody.
Hepatosplenični T-stanični limfom prijavljen je u bolesnika s upalnom bolesti crijeva* liječenih azatioprinom (predlijek 6-merkaptopurina) ili 6-merkaptopurinom, sa ili bez istodobnog liječenja s anti-TNF alfa antitijelima.
Increases in chromosomal aberrations were observed in the peripheral lymphocytes of leukaemic patients, in a renal cell carcinoma patient who received an unstated dose of 6-mercaptopurine and in patients with chronic renal disease treated at doses of 0.4 - 1.0 mg/kg/day.
Povećani broj kromosomskih aberacija zabilježen je u perifernim limfocitima bolesnika s leukemijom, u bolesnika s karcinomom bubrežnih stanica koji je primao nepoznatu dozu 6-merkaptopurina te u bolesnika s kroničnom bolešću bubrega liječenih dozama od 0,4 do 1,0 mg/kg/danu.
Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.
Unutar svake skupine učestalosti nuspojave su prikazane od najozbiljnije prema manje ozbiljnima.
6-mercaptopurine, in common with other antimetabolites, is mutagenic and causes chromosomal aberrations in vitro and in vivo in mice and rats.
6-merkaptopurin, kao i drugi antimetaboliti, mutagen je i uzrokuje kromosomske aberacije in vitro i in vivo u miševa i štakora.
Therefore close monitoring of blood counts is necessary.
Stoga je potrebno pomno praćenje krvne slike.
METHOD AND ROUTE(S) OF ADMINISTRATION Take as directed by your doctor using the dosing syringes provided.
NAČIN I PUT(EVI) PRIMJENE LIJEKA Lijek uzimajte prema uputama liječnika pomoću priloženih štrcaljki za doziranje.
Amber type III glass bottle with tamper evident child-resistant closure (HDPE with expanded polyethylene liner) containing 100 ml of oral suspension.
Smeđa staklena bočica tipa III sa zatvaračem sigurnim za djecu s evidencijom otvaranja (HDPE s ekspandiranim polietilenskim umetkom) koja sadrži 100 ml oralne suspenzije.
A possible association between decreased TPMT activity and secondary leukaemias and myelodysplasia has been reported in individuals receiving 6-mercaptopurine in combination with other cytotoxics (see section 4.8).
Moguća povezanost smanjenja aktivnosti TPMT-a i sekundarnih leukemija i mijelodisplazija uočena je u osoba koji primaju 6-merkaptopurin u kombinaciji s drugim citotoksičnim lijekovima (vidjeti dio 4.8).
Xaluprine contains aspartame (E951) which contains a source of phenylalanine.
Xaluprine sadrži aspartam (E591) koji sadrži izvor fenilalanina.
Patients with little or no inherited TPMT activity are at increased risk for severe toxicity from conventional doses of mercaptopurine and generally require substantial dose reduction.
Bolesnici s naslijeđenom niskom aktivnošću ili nepostojanjem aktivnosti TPMT-a pod povećanim su rizikom od izrazite toksičnosti standardnih doza merkaptopurina te im je općenito potrebno znatno smanjiti dozu.
Careful monitoring of haematological parameters should be conducted during therapy.
Tijekom liječenja potrebno je pažljivo pratiti hematološke parametre.
The 6-mercaptopurine metabolites inhibit de novo purine synthesis and purine nucleotide interconversions.
6-merkaptopurina inhibiraju de novo sintezu purina i interkonverziju purinskih nukleotida.
Ensure that the cap is tightly closed.
Pazite da zatvarač bude čvrsto zatvoren.
However, it is advisable to monitor renal and hepatic function in these patients, and if there is any impairment, consideration should be given to reducing the Xaluprine dose.
No, preporučuje se nadzor funkcije bubrega i jetre u ovih bolesnika te, u slučaju bilo kakvog oštećenja, eventualno smanjenje doze Xaluprina.
Wipe up spillages immediately.
Odmah pobrišite proliveni lijek.
The smaller 1 ml syringe (purple), marked from 0.1 ml to 1 ml, is for measuring doses of less than or equal to 1 ml.
Manja štrcaljka od 1 ml (ljubičasta), graduirana od 0,1 ml do 1 ml, služi za mjerenje doza manjih ili jednakih 1 ml.
During remission induction when rapid cell lysis is occurring, uric acid levels in blood and urine should be monitored as hyperuricaemia and/or hyperuricosuria may develop, with the risk of uric acid nephropathy.
Tijekom indukcije remisije kada dolazi do izrazitog raspadanja stanica, potrebno je pratiti razinu urične kiseline u krvi i mokraći zbog mogućnosti razvoja hiperuricemije i/ili hiperurikozurije te posljedično akutne uratne nefropatije.
Serum antiepileptic levels should be closely monitored during treatment with Xaluprine, making dose adjustments as necessary.
Serumske razine antiepileptika potrebno je pomno pratiti tijekom liječenja Xaluprineom te prema potrebi prilagođavati dozu.
Multiple congenital abnormalities have been reported following maternal 6-mercatopurine treatment in combination with other chemotherapy agents.
Višestruke kongenitalne malformacije zabilježene su nakon liječenja majke 6-merkaptopurinom u kombinaciji s drugim kemoterapijskim agensima.
* In patients with inflammatory bowel disease (IBD), an unlicensed indication.
*U bolesnika s upalnom bolesti crijeva (UBC), nije odobrena indikacija.
Gastrointestinal effects, including nausea, vomiting and diarrhoea and anorexia may be early symptoms of overdose having occurred.
Učinci na probavni sustav, uključujući mučninu, povraćanje i proljev te anoreksiju mogu biti rani simptomu predoziranja.
In any case, close monitoring of blood counts is necessary.
U svakom slučaju, potrebno je pomno praćenje krvne slike.
It also contains sodium methyl parahydroxybenzoate and sodium ethyl parahydroxybenzoate which may cause allergic reaction (possibly delayed).
Također sadrži natrijev metilparahidroksibenzoat i natrijev etilparahidroksibenzoat koji mogu uzrokovati alergijske reakcije (koje mogu biti odgođene).
The optimal starting dose for homozygous deficient patients has not been established (see section 4.4).
Optimalna početna doza za bolesnike koji su homozigoti za deficit enzima nije utvrđena (vidjeti dio 4.4).
Two dosing syringes (a purple syringe graduated to 1 ml and a white syringe graduated to 5 ml) are provided for accurate measurement of the prescribed dose of the oral suspension.
Dvije štrcaljke za doziranje (ljubičasta graduirana štrcaljka od 1 ml i bijela graduirana štrcaljka od 5 ml) dostupne su za točnu primjenu propisane doze oralne suspenzije.
Monitoring of the INR (International Normalised Ratio) value is recommended during concomitant administration with oral anticoagulants.
Preporučuje se praćenje INR-a tijekom istodobne primjene s oralnim antikoagulansima.
Patients with inherited mutated NUDT15 gene are at increased risk for severe 6-mercaptopurine toxicity, (see 4.4).
Bolesnici s naslijeđenim mutiranim genom NUDT15 pod povećanim su rizikom od teške toksičnosti 6-merkaptopurina (vidjeti 4.4).
Xaluprine should not be handled by women who are or planning to be pregnant or breast-feeding.
Xaluprineom ne smiju rukovati žene koje planiraju zatrudnjeti ili dojiti.
Haematological toxicity is likely to be more profound with chronic overdose than with a single ingestion of Xaluprine.
Hematološka toksičnost bit će izraženija kod kroničnog predoziranja nego pri primjeni jedne doze Xaluprina.
Effects of mercaptopurine on other medicinal products Concomitant administration of yellow fever vaccine is contraindicated, due to the risk of fatal disease in immunocompromised patients (see section 4.3)
Istodobna primjena cjepiva protiv žute groznice kontraindicirana je zbog rizika od smrtonosne bolesti u imunokompromitiranih bolesnika (vidjeti dio 4.3)
6-mercaptopurine is also subject to S-methylation by the enzyme thiopurine S-methyltransferase (TPMT), yielding methylmercaptopurine, which is inactive.
6-merkaptopurin također prolazi S-metilaciju pomoću tiopurin S-metiltransferaze (TPMT) kojom nastaje metilmerkaptopurin, koji je inaktivan.
When administered orally at a dosage of 75 mg/m2 to 7 paediatric patients, the bioavailability averaged 16% of the administered dose, with a range of 5 to 37%.
7 pedijatrijskih bolesnika bioraspoloživost je u prosjeku iznosila 16% primijenjene doze s rasponom od 5 do 37%.
One ml of suspension contains 3 mg aspartame, 1 mg methyl hydroxybenzoate (as the sodium salt), 0.5 mg ethyl hydroxybenzoate (as the sodium salt) and sucrose (trace).
Jedan ml suspenzije sadrži 3 mg aspartama, 1 mg metilhidroksibenzoata (u obliku natrijeve soli), 0,5 mg etilhidroksibenzoata (u obliku natrijeve soli) i saharozu (u tragovima).
If you forget to take Xaluprine
Ako ste zaboravili uzeti Xaluprine
The leucocyte and platelet counts continue to fall after treatment is stopped, so at the first sign of an abnormally large fall in the counts, treatment should be interrupted immediately.
Broj leukocita i trombocita se nastavlja smanjivati i nakon završetka liječenja pa je odmah po pojavi znatnijeg pada broja stanica liječenje potrebno prekinuti.
Cases of symptomatic hypoglycaemia have been reported in children with ALL receiving 6-mercaptopurine (see section 4.8).
Slučajevi simptomatske hipoglikemije prijavljeni su u djece s ALL-om koja primaju 6-merkaptopurin (vidjeti dio 4.8).
MIAS Pharma Limited Suite 2, Stafford House, Strand Road Postmarnock, Co. Dublin D13H525
MIAS Pharma Limited Suite 2, Stafford House, Strand Road
For mercaptopurine there is a lack of modern clinical documentation which can serve as support for accurately determining the frequency of adverse reactions.
Za merkaptopurin nedostaje novija klinička dokumentacija na temelju koje bi sa mogla točno procijeniti učestalost nuspojava.
The principal toxic effect is on the bone marrow, resulting in myelosuppression.
Glavno toksično djelovanje je na koštanu srž, a rezultira mijelosupresijom.
Bone marrow suppression is reversible if 6-mercaptopurine is withdrawn early enough..
Supresija koštane srži je reverzibilna ako se liječenje 6-merkaptopurinom prekine dovoljno rano.
The active substance is mercaptopurine (as monohydrate).
Djelatna tvar je merkaptopurin (u obliku hidrata).
Patients should be closely monitored for dose related adverse reactions.
Potrebno je pažljivo pratiti bolesnike zbog razvoja nuspojava povezanih s dozom.
Patients should be closely monitored for dose related adverse reactions (see section 4.4).
Potrebno je pažljivo pratiti bolesnike zbog mogućeg razvoja nuspojava povezanih s dozom (vidjeti dio 4.4).
Put the cap back on the bottle with the adaptor left in place.
12. Vratite zatvarač na bočicu tako da nastavak ostane na mjestu.
These patients generally require dose reduction; particularly those being NUDT15 variant homozygotes (see 4.4).
Tim je bolesnicima općenito potrebno smanjiti dozu, osobito onima koji su homozigoti za varijantu NUDT15 (vidjeti 4.4).
Some patients with inflammatory bowel disease who have received 6-mercaptopurine have developed a rare and aggressive type of cancer called Hepatosplenic T-cell Lymphoma (see section 4, Possible side effects).
U nekih bolesnika s upalnom bolesti crijeva koji su primali 6-merkaptopurin došlo je do razvoja rijetkog i agresivnog tipa raka pod nazivom hepatosplenični T-stanični limfom (pogledajte dio 4.
1 ml and 5 ml dosing syringes.
Štrcaljke za doziranje od 1 ml i 5 ml.
They generally require dose reduction, particularly those being NUDT15 variant homozygotes (see 4.2).
Njima je općenito potrebno smanjiti dozu, osobito onima koji su homozigoti za varijantu NUDT15 (vidjeti
Marketing Authorisation Holder Nova Laboratories Ireland Limited 3rd Floor, Ulysses House Foley Street, Dublin 1
Nositelj odobrenja za stavljanje lijeka u promet Nova Laboratories Ireland Limited 3rd Floor, Ulysses House
Active measures (such as the use of activated charcoal or gastric lavage) may not be effective in the event of 6-mercaptopurine overdose unless the procedure can be undertaken within 60 minutes of ingestion.
Aktivne mjere (poput uporabe aktivnog ugljena ili ispiranja želuca) možda neće biti djelotvorne kod 6-merkaptopurina,
May be harmful for people with phenylketonuria.
Može biti štetan za osobe koje boluju od fenilketonurije.
Patients with inherited mutated NUDT15 gene are at increased risk for severe 6-mercaptopurine toxicity, such as early leukopenia and alopecia, from conventional doses of thiopurine therapy.
Bolesnici s naslijeđenim mutiranim genom NUDT15 pod povećanim su rizikom od teške toksičnosti 6-merkaptopurina, kao što su rana leukopenija i alopecija, od uobičajenih doza tiopurina.
One ml of suspension contains 20 mg of mercaptopurine monohydrate.
Jedan ml suspenzije sadrži 20 mg merkaptopurin hidrata.
No studies on the effect on the ability to drive and use machines have been performed.
4.7 Utjecaj na sposobnost upravljanja vozilima i rada sa strojevima Nisu provedena ispitivanja utjecaja na sposobnost upravljanja vozilima i rada sa strojevima.
- Allergic reaction, the signs may include: o skin rashes o high temperature o joint pain o swollen face
Alergijske reakcije, znakovi mogu uključivati: - osip na koži
You should take your medicine at least 1 hour before or 2 hours after having milk or dairy products.
Xaluprine je potrebno uzeti najmanje sat vremena prije ili 2 sata nakon konzumiranja mlijeka ili mliječnih proizvoda.
Hydration and urine alkalinisation may minimize potential renal complications.
Hidracija i alkalizacija mokraće mogu smanjiti rizik od nastanka bubrežnih komplikacija.
Xaluprine also contains sodium methyl parahydroxybenzoate (E219) and sodium ethyl parahydroxybenzoate (E215) which may cause allergic reactions (possibly delayed).
Xaluprine također sadrži natrijev metilparahidroksibenzoat (E219) i natrijev etilparahidroksibenzoat (E215) koji mogu uzrokovati alergijske reakcije (koje mogu biti odgođene).
If Xaluprine comes into contact with skin or mucosa, it should be washed immediately and thoroughly with soap and water.
Ako Xaluprine dođe u dodir s kožom ili sluznicama,treba ih odmah temeljito isprati sapunom i vodom.
The histological findings in man have shown hepatic necrosis and biliary stasis
Histološke analize u ljudi pokazale su nekrozu jetre i zastoj žuči.
Always use the syringes provided to take your medicine.
Za uzimanje lijeka uvijek koristite priložene štrcaljke.
The dose is governed by cautiously monitored haematotoxicity and the dose should be carefully adjusted to suit the individual patient in accordance with the employed treatment protocol.
Doza se pažljivo prilagođava uzimajući u obzir uočenu hematotoksičnost i individualne potrebe bolesnika u okviru aktivnog protokola liječenja.
INFORMATION IN BRAILLE Xaluprine 20 mg/ml
Xaluprine 20 mg/ml
There is low entry of 6-mercaptopurine into the cerebrospinal fluid.
Prolazak 6-merkaptopurina u cerebrospinalni likvor je nizak.
Xaluprine contains sucrose.
Xaluprine sadrži saharozu.
Allopurinol and other xanthine oxidase inhibitors decrease the rate of catabolism of 6-mercaptopurine.
Kombinacija s inhibitorima ksantin oksidaze Alopurinol i drugi inhibitori ksantin oksidaze smanjuju brzinu katabolizma 6-merkaptopurina.
The patient should be instructed to discontinue Xaluprine immediately if jaundice becomes apparent (see section 4.8).
Bolesnike je potrebno savjetovati da u slučaju pojave žutice odmah prekinu liječenje Xaluprineom (vidjeti dio 4.8).
BSA (m2) Dose (mg)
Doza (mg)
Prior exposure to or infection with varicella zoster virus should be taken into consideration prior to starting treatment.
Prije početka liječenja trebalo bi uzeti u obzir je li bolesnik prethodno izložen virusu varicella zoster ili zaražen virusom varicella zoster.
Your doctor or pharmacist will advise which syringe to use depending on the dose that has been prescribed.
Vaš liječnik ili ljekarnik savjetovat će vam koju ćete štrcaljku upotrijebiti za dozu koja Vam je propisana.
5.3 Preclinical safety data
5.3 Neklinički podaci o sigurnosti primjene Genotoksičnost
The first step is catalysed by hypoxanthine-guanine phosphoribosyl transferase yielding thioinosine monophosphate (TIMP).
Prvi korak katalizira hipoksantin-gvaninfosforibozil transferaza pri čemu nastaje tioinozin monofosfat.
The main adverse reaction of treatment with 6-mercaptopurine is bone marrow suppression leading to leucopenia and thrombocytopenia.
Glavna nuspojava liječenja 6-merkaptopurinom je supresija koštane srži koja dovodi do leukopenije i trombocitopenije.
Genotypic testing of NUDT15 variants may be considered before initiating 6-mercaptopurine therapy.
Prije početka liječenja 6-merkaptopurinom može se uzeti u obzir genotipizacija varijanti NUDT15.
Cases of neutropenic sepsis have been reported in patients receiving 6-mercaptopurine for ALL.
Slučajevi neutropenične sepse prijavljeni su u bolesnika koji primaju 6-merkaptopurin za ALL.
Serologic testing prior to starting treatment should be considered with respect to hepatitis B. Local guidelines may be considered, including prophylactic therapy for cases which have been confirmed positive by serologic testing.
Mogu se razmotriti lokalne smjernice, uključujući profilaktičko liječenje za slučajeve koji su se na serološkom ispitivanju pokazali pozitivni.
Both TIMP and mTIMP are inhibitors of phosphoribosyl pyrophosphate amidotransferase, an enzyme which is important in de novo purine synthesis.
I tioinozin monofosfat i metiltioinozin monofosfat su inhibitori fosforibozil pirofosfat amidotransferaze, enzima koji je važan u de novo sintezi purina.
TPMT also catalyses the S-methylation of the principle nucleotide metabolite, TIMP, to form methylthioinosine monophosphate (mTIMP).
Međutim, TPMT također katalizira S-metilaciju glavnog nukleotidnog metabolita tioinozin monofosfata pri čemu nastaje metiltioinozin monofosfat.
Your pack of Xaluprine contains a bottle of medicine, a cap, a bottle adaptor and two dosing syringes (a purple 1 ml syringe and a white 5 ml syringe).
Vaše pakiranje Xaluprinea sadrži bočicu lijeka, zatvarač, nastavak za bočicu i dvije štrcaljke za doziranje (ljubičasta štrcaljka od 1 ml i bijela od 5 ml).
- Any unexpected bruising or bleeding, as this could mean that too few blood cells of a particular type are being produced
Bilo koji znakovi vrućice ili infekcije (grlobolja, bolna usta ili problemi s mokrenjem) Bilo kakav neočekivani nastanak modrica ili krvarenje, jer to može značiti da se stvara premalo krvnih stanica određenog tipa.
Xaluprine is cytotoxic.
Xaluprine je citotoksičan.
Evidence of the teratogenicity of 6-mercaptopurine in humans is equivocal.
Teratogenost 6-merkaptopurina u ljudi nije definitivno potvrđena.
Mutagenicity and carcinogenicity
Mutagenost i kancerogenost
How to take Xaluprine
Kako uzimati Xaluprine
Arthralgia, skin rash, drug fever
Artralgija, osip na koži, jatrogena vrućica
Pancreatitis, oral ulceration
Pankreatitis, ulceracije u usnoj šupljini
Xaluprine 20 mg/ml oral suspension mercaptopurine
Xaluprine 20 mg/ml oralna suspenzija merkaptopurin
Xaluprine contact with skin or mucous membrane must be avoided.
Mora se izbjegavati kontakt Xaluprina s kožom ili sluznicama.
Shake the bottle vigorously for at least 30 seconds to ensure the medicine is well mixed (figure 1).
2. Snažno tresite bočicu najmanje 30 sekundi kako biste osigurali da je lijek dobro promiješan
Push the tip of the dosing syringe into the hole in the adaptor (figure 4).
Gurnite vrh štrcaljke za doziranje u otvor nastavka (slika 4).
6-mercaptopurine is an inactive pro-drug which acts as a purine antagonist but requires cellular uptake and intracellular anabolism to thioguanine nucleotides for cytotoxicity.
6-merkaptopurin je neaktivni predlijek koji djeluje kao antagonist purina, ali mu je za citotoksični učinak potreban unos u stanicu i unutarstanična dogradnja do tiogvaninskih nukleotida.
Excipients with known effect
Pomoćna(e) tvar(i) s poznatim učinkom:
Biliary stasis, hepatotoxicity
Zastoj žuči, hepatoksičnost
Other side effects (the frequency is unknown) - a rare type of cancer (hepatosplenic T-cell lymphoma), (see section 2, Warnings and
Ostale nuspojave (učestalost nepoznata) - rijetki tip raka (hepatosplenični T-stanični limfom), (pogledajte dio 2. Upozorenja i mjere opreza) - Osjetljivost na sunčevu svjetlost s reakcijama na koži
The intracellular anabolism of 6-merpactopurine is catalysed by several enzymes to eventually form 6-thioguanine nucleotides (TGNs), but a variety of intermediary TGNs are formed en route to the TGNs.
Biotransformacija Unutarstaničnu dogradnju 6-merkaptopurina katalizira nekoliko enzima do konačnog stvaranja nukleotida 6-tiogvanina, ali pri tome nastaje niz međuspojeva nukleotida 6-tiogvanina.
100 ml glass bottle Bottle adaptor
Staklena bočica od 100 ml Nastavak za bočicu
The expiry date refers to the last day of that month, - Do not store above 25°C.
Rok valjanosti odnosi se na zadnji dan navedenog mjeseca.
Rare (affects less than 1 in 1,000 people) - hair loss - in men: temporary low sperm count - swollen face - various types of cancers including blood, lymph and skin cancers
- u muškaraca: privremeni pad količine sperme - otečeno lice - različite vrste raka uključujući rak krvi, limfnog sustava i kože